ADA Scientific Sessions 2026 Abstract
Continuous Glucose Monitoring in Type 2 Diabetes Managed with Basal Insulin plus SGLT2 Inhibitor and/or GLP-1 Agonist: Subgroup Analysis from the FreeDM2 Trial
Trial in peopleInterventions
Papers by Katharine Barnard-Kelly
1 result